Cargando…

Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study

BACKGROUND AND AIMS: The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Riasi, Fatemeh, Ataei Azimi, Sajjad, Allahyari, Abolghasem, Moeini Nodeh, Mohammad, Shakeri, Mohammad T., Kamandi, Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684988/
https://www.ncbi.nlm.nih.gov/pubmed/38033714
http://dx.doi.org/10.1002/hsr2.1716
_version_ 1785151530448453632
author Riasi, Fatemeh
Ataei Azimi, Sajjad
Allahyari, Abolghasem
Moeini Nodeh, Mohammad
Shakeri, Mohammad T.
Kamandi, Mostafa
author_facet Riasi, Fatemeh
Ataei Azimi, Sajjad
Allahyari, Abolghasem
Moeini Nodeh, Mohammad
Shakeri, Mohammad T.
Kamandi, Mostafa
author_sort Riasi, Fatemeh
collection PubMed
description BACKGROUND AND AIMS: The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regimens with and without vincristine reduction in DLBCL patients. METHODS: This retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R‐CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared. RESULTS: Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R‐CHOP regimen (p > 0.05). Besides, no difference was observed in the 1‐year overall survival (OS) and progression‐free survival (PFS) of the patients in the two groups treated with R‐CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R‐CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R‐CHOP treatment regimen had no relationship with the 1‐year OS and PFS of the DLBCL patients (hazard ratio [HR](OS) = 1.59, 95% confidence interval [CI]: 3.67–0.690, HR(PFS) = 1.67, 95% CI: 0.798–3.82). CONCLUSION: The results of this study showed that the reduction of vincristine from the R‐CHOP regimen in the DLBCL patients was not likely to make a difference in the 1‐year OS and PFS of the patients. However, further studies are needed on the issue.
format Online
Article
Text
id pubmed-10684988
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106849882023-11-30 Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study Riasi, Fatemeh Ataei Azimi, Sajjad Allahyari, Abolghasem Moeini Nodeh, Mohammad Shakeri, Mohammad T. Kamandi, Mostafa Health Sci Rep Original Research BACKGROUND AND AIMS: The effect of stopping or reducing the dose of vincristine in diffuse large B‐cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R‐CHOP treatment regimens with and without vincristine reduction in DLBCL patients. METHODS: This retrospective study was conducted on newly diagnosed DLBCL patients during 2018–2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R‐CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared. RESULTS: Overall, 269 patients with DLBCL were included in this study, 15.99% of whom (n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R‐CHOP regimen (p > 0.05). Besides, no difference was observed in the 1‐year overall survival (OS) and progression‐free survival (PFS) of the patients in the two groups treated with R‐CHOP regimen with and without vincristine reduction (p > 0.05). The complete remission rates of the patients treated with R‐CHOP regimen with and without vincristine (p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R‐CHOP treatment regimen had no relationship with the 1‐year OS and PFS of the DLBCL patients (hazard ratio [HR](OS) = 1.59, 95% confidence interval [CI]: 3.67–0.690, HR(PFS) = 1.67, 95% CI: 0.798–3.82). CONCLUSION: The results of this study showed that the reduction of vincristine from the R‐CHOP regimen in the DLBCL patients was not likely to make a difference in the 1‐year OS and PFS of the patients. However, further studies are needed on the issue. John Wiley and Sons Inc. 2023-11-28 /pmc/articles/PMC10684988/ /pubmed/38033714 http://dx.doi.org/10.1002/hsr2.1716 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Riasi, Fatemeh
Ataei Azimi, Sajjad
Allahyari, Abolghasem
Moeini Nodeh, Mohammad
Shakeri, Mohammad T.
Kamandi, Mostafa
Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
title Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
title_full Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
title_fullStr Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
title_full_unstemmed Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
title_short Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
title_sort prognosis and complete remission rate of diffuse large b‐cell lymphoma patients in standard r‐chop with reduction of vincristine: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684988/
https://www.ncbi.nlm.nih.gov/pubmed/38033714
http://dx.doi.org/10.1002/hsr2.1716
work_keys_str_mv AT riasifatemeh prognosisandcompleteremissionrateofdiffuselargebcelllymphomapatientsinstandardrchopwithreductionofvincristinearetrospectivestudy
AT ataeiazimisajjad prognosisandcompleteremissionrateofdiffuselargebcelllymphomapatientsinstandardrchopwithreductionofvincristinearetrospectivestudy
AT allahyariabolghasem prognosisandcompleteremissionrateofdiffuselargebcelllymphomapatientsinstandardrchopwithreductionofvincristinearetrospectivestudy
AT moeininodehmohammad prognosisandcompleteremissionrateofdiffuselargebcelllymphomapatientsinstandardrchopwithreductionofvincristinearetrospectivestudy
AT shakerimohammadt prognosisandcompleteremissionrateofdiffuselargebcelllymphomapatientsinstandardrchopwithreductionofvincristinearetrospectivestudy
AT kamandimostafa prognosisandcompleteremissionrateofdiffuselargebcelllymphomapatientsinstandardrchopwithreductionofvincristinearetrospectivestudy